Drug combination delivered by nanoparticles may help in melanoma treatment

The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient.

Celecoxib and Plumbagin work together to kill melanoma cells when used in a specific ratio. Researchers used microscopic particles called nanoparticles to deliver the drugs directly to the cancer cells. These particles are several hundred times smaller than the width of a hair and can be loaded with medications.

"Loading multiple drugs into nanoparticles is one innovative approach to deliver multiple cancer drugs to a particular site where they need to act, and have them released at that optimal cancer cell-killing ratio," said Raghavendra Gowda, assistant professor of pharmacology, who is the lead author on the study. "Another advantage is that by combining the drugs, lower concentrations of each that are more effective and less toxic can be used."

Celecoxib and Plumbagin cannot be taken by mouth, because the drugs do not enter the body well this way and cannot be used together in the ratio needed because of toxicity to the patient.

However, CelePlum-777 can be injected intravenously without toxicity. Because of its small size, it also accumulates inside the tumors where it then releases the drugs to kill the cancer cells. Researchers report their results in the journals Molecular Cancer Therapeutics and Cancer Letters.

"This drug is the first of a new class, loaded with multiple agents to more effectively kill melanoma cells, that has potential to reduce the possibility of resistance development," said senior author Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery; director of the Penn State Melanoma and Skin Cancer Center and member of Penn State Cancer Institute. "There is no drug like it in the clinic today and it is likely that the next breakthrough in melanoma treatment will come from a drug like this one."

The researchers showed the results of CelePlum-777 on killing cancer cells growing in culture dishes and in tumors growing in mice following intravenous injection. The drug prevented tumor development in mice with no detectable side effects and also prevented proteins from enabling uncontrolled cancer cell growth.

More research is required by the Food and Drug Administration before CelePlum-777 can be tested in humans through clinical trials. Penn State has patented this discovery and licensed it to Cipher Pharmaceuticals, which will perform the next series of FDA-required tests.

Other researchers who participated in these studies are Gregory Kardos, class of 2014 graduate student, genetics; Arati Sharma, associate professor of pharmacology and Penn State Cancer Institute, and Sanjay Singh, postdoctoral fellow. This work was undertaken through a collaboration of scientists in the Melanoma and Skin Cancer Center, Melanoma Therapeutics Program, Department of Pharmacology, and Penn State Cancer Institute.

National Institutes of Health; The Foreman Foundation for Melanoma Research; The Geltrude Foundation for Melanoma Research; The Penn State Melanoma and Skin Cancer Center; the J. Roland Gilbert, Mary R. Gilbert and Elizabeth A. Gilbert Memorial Fund; The James Paul Sutton Medical Research Fund, and the Penn State Chocolate Tour Cancer Research Fund funded this research.

Gowda R, Kardos G, Sharma A, Singh S, Robertson GP.
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.
Mol Cancer Ther. 2017 Mar;16(3):440-452. doi: 10.1158/1535-7163.MCT-16-0285.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]